[Oral administration of beraprost sodium did not exacerbate pulmonary hypertension with CREST syndrome].
نویسندگان
چکیده
62.4倍,抗 セ ン トロ メ ア 抗 体1,280倍.動 脈 血 ガ ス 分 析:pH 7.482, PaOz 56.5Torr, PaCO2 34 .2 Torr.肺 機 能 は%肺 活 量80.5%,1秒 率82.5% と正常範囲であった.胸 部X線 上は心胸郭比57,4 %,右 肺 動脈 拡 大,右 第2弓,左 第2,4弓 の 突出,両 側下肺野に網状影 などを認めた.心 電 図は正常 洞 調律 で,電 気 軸 は+60°,II誘 導 に 肺性P波,V1~V3に 陰性T波, SV1+RV5=5.3mV であった.心 臓超音波検査(図1)の 左 室短軸 断層像で は,心 室 中隔の左室側への圧排 所見 を 認めた.パ ルス ドップラー による右室流出路波 形で は,加 速時間の右室駆 出時間 に対す る比 は 0.2と 低 値 で,推 定 肺 動 脈 圧 は75/22mmHgで あった.右 心 カテーテル検査で,肺 動脈楔 入圧 7mmHg,肺 動脈 圧77/23 mmHg(平 均41 mmHg),右 室 収 縮 期 圧69mmHg,右 房 圧5 mmHg,心 拍 出量4.22L/分 と前毛細管性 肺高血 圧 を認めた.心 内短絡路 は認めず,肺 換気血流 シ ンチでは ミスマ ッチを認 めなか った,以 上 よ りCREST症 候群 に合併 した肺血 管性 肺高 血圧 症 と診断 した.そ の後在宅酸素療法 を開始 し, 高 血圧 症 に対 して はニ フェ ジ ピ ン10mg/日,
منابع مشابه
Combination therapy with oral sildenafil and beraprost for pulmonary arterial hypertension associated with CREST syndrome.
Pulmonary arterial hypertension (PAH) is commonly associated with CREST (Calcinosis, Raynaud phenomenon, Esophageal motility disorders, Sclerodactyly, and Telangiectasia) syndrome. Sildenafil, an oral phosphodiesterase type-5 inhibitor, may offer benefits in the pharmacological management of PAH. However, little is known about the long-term hemodynamic effects of sildenafil, and the potential r...
متن کاملCARDIOVASCULAR MEDICINE Oral beraprost sodium improves exercise capacity and ventilatory efficiency in patients with primary or thromboembolic pulmonary hypertension
Objective: To investigate the effect of beraprost sodium, an orally active prostacyclin analogue, on exercise capacity and ventilatory efficiency in patients with primary pulmonary hypertension and chronic thromboembolic pulmonary hypertension. Patients and design: Symptom limited cardiopulmonary exercise testing was performed before and 3 (1) months (mean (SEM)) after beraprost treatment in 30...
متن کاملOral beraprost sodium improves exercise capacity and ventilatory efficiency in patients with primary or thromboembolic pulmonary hypertension.
OBJECTIVE To investigate the effect of beraprost sodium, an orally active prostacyclin analogue, on exercise capacity and ventilatory efficiency in patients with primary pulmonary hypertension and chronic thromboembolic pulmonary hypertension. PATIENTS AND DESIGN Symptom limited cardiopulmonary exercise testing was performed before and 3 (1) months (mean (SEM)) after beraprost treatment in 30...
متن کاملBosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids.
Primary pulmonary hypertension (PPH) is a life-threatening disease. Nonparenteral prostanoids, i.e. aerosolised iloprost or oral beraprost sodium show beneficial therapeutic effects but are not sufficiently active in all patients with this devastating disease. The purpose of the present study was to determine whether the endothelin-receptor antagonist bosentan is safe and effective in patients ...
متن کاملOrally active prostacyclin analogue in primary pulmonary hypertension.
Primary pulmonary hypertension is a disease of unknown aetiology that is progressive and uniformly fatal. However, substantial improvement in the duration and quality of life has been reported in patients who have received long-term intravenous prostacyclin (PGI2) infusion. But this treatment is more uncomfortable for patients and potentially more hazardous than oral therapy. On the other hand,...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine
دوره 90 5 شماره
صفحات -
تاریخ انتشار 2001